AFT Pharmaceuticals Limited (AFT.NZ)
NZD 2.8
(0.0%)
NZD 2.8
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 165.25 Million NZD | 11.61% |
| 2023 | 148.06 Million NZD | 21.6% |
| 2022 | 121.76 Million NZD | 15.82% |
| 2021 | 105.13 Million NZD | 20.77% |
| 2020 | 87.05 Million NZD | 36.88% |
| 2019 | 63.59 Million NZD | 12.35% |
| 2018 | 56.6 Million NZD | -2.8% |
| 2017 | 58.23 Million NZD | -1.02% |
| 2016 | 58.83 Million NZD | 77.14% |
| 2015 | 33.21 Million NZD | 30.42% |
| 2014 | 25.46 Million NZD | 14.48% |
| 2013 | 22.24 Million NZD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 FY | 165.25 Million NZD | 11.61% |
| 2024 Q3 | 165.25 Million NZD | 4.02% |
| 2024 Q1 | 158.87 Million NZD | 7.3% |
| 2024 Q4 | 165.25 Million NZD | 0.0% |
| 2024 Q2 | 158.87 Million NZD | 0.0% |
| 2023 Q3 | 148.06 Million NZD | 17.23% |
| 2023 Q4 | 148.06 Million NZD | 0.0% |
| 2023 FY | 148.06 Million NZD | 21.6% |
| 2023 Q1 | 126.3 Million NZD | 3.73% |
| 2023 Q2 | 126.3 Million NZD | 0.0% |
| 2022 Q1 | 105.7 Million NZD | 0.55% |
| 2022 Q4 | 121.76 Million NZD | -4.37% |
| 2022 Q3 | 127.32 Million NZD | 20.45% |
| 2022 FY | 121.76 Million NZD | 15.82% |
| 2022 Q2 | 105.7 Million NZD | 0.0% |
| 2021 Q2 | 93.98 Million NZD | 0.0% |
| 2021 Q1 | 93.98 Million NZD | 7.96% |
| 2021 Q3 | 105.13 Million NZD | 11.86% |
| 2021 Q4 | 105.13 Million NZD | 0.0% |
| 2021 FY | 105.13 Million NZD | 20.77% |
| 2020 Q4 | 87.05 Million NZD | 0.0% |
| 2020 Q2 | 83.23 Million NZD | 0.0% |
| 2020 Q1 | 83.23 Million NZD | 30.88% |
| 2020 FY | 87.05 Million NZD | 36.88% |
| 2020 Q3 | 87.05 Million NZD | 4.59% |
| 2019 Q4 | 63.59 Million NZD | 0.0% |
| 2019 FY | 63.59 Million NZD | 12.35% |
| 2019 Q3 | 63.59 Million NZD | 7.05% |
| 2019 Q2 | 59.4 Million NZD | 0.0% |
| 2019 Q1 | 59.4 Million NZD | 4.95% |
| 2018 Q1 | 50.36 Million NZD | -13.5% |
| 2018 Q4 | 56.6 Million NZD | 0.0% |
| 2018 Q3 | 56.6 Million NZD | 12.38% |
| 2018 Q2 | 50.36 Million NZD | 0.0% |
| 2018 FY | 56.6 Million NZD | -2.8% |
| 2017 FY | 58.23 Million NZD | -1.02% |
| 2017 Q2 | 53.81 Million NZD | 0.0% |
| 2017 Q1 | 53.81 Million NZD | -17.6% |
| 2017 Q3 | 58.32 Million NZD | 8.39% |
| 2017 Q4 | 58.23 Million NZD | -0.16% |
| 2016 Q3 | 65.3 Million NZD | 60.5% |
| 2016 Q2 | 40.68 Million NZD | 0.0% |
| 2016 FY | 58.83 Million NZD | 77.14% |
| 2016 Q4 | 65.3 Million NZD | 0.0% |
| 2016 Q1 | 40.68 Million NZD | 22.51% |
| 2015 Q4 | 33.21 Million NZD | 0.0% |
| 2015 Q1 | - NZD | 0.0% |
| 2015 Q3 | 33.21 Million NZD | 0.0% |
| 2015 FY | 33.21 Million NZD | 30.42% |
| 2014 FY | 25.46 Million NZD | 14.48% |
| 2013 FY | 22.24 Million NZD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Greenfern Industries Limited | 3.21 Million NZD | -5039.507% |
| Rua Bioscience Limited | 7.73 Million NZD | -2035.163% |